We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

86 hedge funds and large institutions have $176M invested in Akebia Therapeutics in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 33 increasing their positions, 27 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 27

20% more capital invested

Capital invested by funds: $147M → $176M (+$29.2M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

8% less funds holding

Funds holding: 93 → 86 (-7)

47% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 15

49% less call options, than puts

Call options by funds: $1.47M | Put options by funds: $2.86M

Holders
86
Holders Change
-7
Holders Change %
-7.53%
% of All Funds
2.29%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
33
Reduced
27
Closed
15
Calls
$1.47M
Puts
$2.86M
Net Calls
-$1.4M
Net Calls Change
-$46K

Top Buyers

1
ACA
Avoro Capital Advisors
New York
+$2.74M
2
GTC
Ghost Tree Capital
New York
+$2.55M
3
NCM
Nantahala Capital Management
Connecticut
+$1.99M
4
Marshall Wace
Marshall Wace
United Kingdom
+$1.36M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.08M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.43M
2
EAM
EverPoint Asset Management
Connecticut
-$1.5M
3
First Manhattan
First Manhattan
New York
-$1.35M
4
TC
TFS Capital
Pennsylvania
-$1.3M
5
LCM
Landscape Capital Management
New Jersey
-$891K
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
101
IFP Advisors
Florida
– +$238 +28 New
1 2 3 4
5

AKBA Hedge Fund Activity: Q3 2016 in Review

86 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2016, worth a combined $176M — up 20% from $147M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of AKBA and 8 opened new positions — a net loss of 7 holders — while 27 trimmed existing stakes and 33 added.

The largest buyer was Avoro Capital Advisors, adding an estimated $2.74M. The largest seller was Fidelity Investments, cutting an estimated $6.43M.

  • 86 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2016, down from 93 in Q2 2016.
  • Funds reported $176M of Akebia Therapeutics stock for Q3 2016, up 20% quarter-over-quarter.
  • 8 funds opened new Akebia Therapeutics positions in Q3 2016 and 15 closed out, a net change of -7 holders.
  • The largest Akebia Therapeutics buyer in Q3 2016 was Avoro Capital Advisors, an estimated $2.74M added.
  • The largest Akebia Therapeutics seller in Q3 2016 was Fidelity Investments, an estimated $6.43M sold.

Based on aggregated 13F filings for Q3 2016.